Emerging Treatments for Retinopathy of Prematurity

REFERENCES

• Terry T L. Retrolental fibroplasia in the premature infant: V. Further studies on fibroplastic overgrowth of the persistent tunica vasculosa lentis. Tran Am Ophthalmol Soc 1944; 44: 383–396
   Google Scholar
• Lutty G A, Chan-Ling T, Phelps D L, et al. Proceedings of the third international symposium on retinopathy of prematurity: An update on ROP from the lab to the nursery (November 2003, Anaheim, California). Mol Vis 2006; 12: 532–580
   PubMed Web of Science ®Google Scholar
• Smith L E. Pathogenesis of retinopathy of prematurity. Semin Neonatol 2003; 8: 469–473
   PubMedGoogle Scholar
• Tasman W, Patz A, McNamara J A, et al. Retinopathy of prematurity: The life of lifetime disease. Am J Ophthalmol 2006; 141: 167–174
   Google Scholar
• Campbell K. Intensive oxygen therapy as a possible cause of retrolental fibroplasia; A clinical approach. Med J Aust 1951; 2: 48–50
   PubMedGoogle Scholar
• Patz A, Hoeck L E, De La Cruz E. Studies on the effect of high oxygen administration in retrolental fibroplasia. I. Nursery observations. Am J Ophthalmol 1952; 35: 1248–1253
   PubMed Web of Science ®Google Scholar
• Ashton N, Ward B, Serpell G. Role of oxygen in the genesis of retrolental fibroplasia; A preliminary report. Br J Ophthalmol 1953; 37: 513–520
   PubMed Web of Science ®Google Scholar
• Kinsey V E, Arnold H J, Kalina R E, et al. PaO2 levels and retrolental fibroplasia: A report of the cooperative study. Pediatrics 1977; 60: 655–668
   PubMed Web of Science ®Google Scholar
• Lofqvist C, Andersson E, Sigurdsson J, et al. Longitudinal postnatal weight and insulin-like growth factor I measurements in the prediction of retinopathy of prematurity. Arch Ophthalmol 2006; 124: 1711–1718
   PubMedGoogle Scholar
• The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Incidence and early course of retinopathy of prematurity. Ophthalmology 1991; 98: 1628–1640
   Google Scholar
• The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: One-year outcome—Structure and function. Arch Ophthalmol 1990; 108: 1408–1416
   Google Scholar
• Good W V, Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc 2004; 102: 233–250
   PubMedGoogle Scholar
• Hubbard G B, 3rd. Surgical management of retinopathy of prematurity. Curr Opin Ophthalmol 2008; 19: 384–390
   PubMed Web of Science ®Google Scholar
• Silverman W A, Flynn J T. Contemporary Issues in Fetal and Neonatal Medicine. Retinopathy of Prematurity. Blackwell Scientific, Boston 1985
   Google Scholar
• Silverman W A. A cautionary tale about supplemental oxygen: The albatross of neonatal medicine. Pediatrics 2004; 113: 394–396
   PubMed Web of Science ®Google Scholar
• Kinsey V E. Retrolental fibroplasia; Cooperative study of retrolental fibroplasia and the use of oxygen. AMA Arch Ophthalmol 1956; 56: 481–543
   PubMed Web of Science ®Google Scholar
• Avery M E. Recent increase in mortality from hyaline disease. J Pediatr 1960; 57: 553–559
   PubMed Web of Science ®Google Scholar
• McDonald A D. The aetiology of spastic diplegia. A synthesis epidemiological and pathological evidence. Dev Neurol 1964; 11: 277–285
   Google Scholar
• Cross K W. Cost of preventing retrolental fibroplasia?. Lancet 1973; 2: 954–956
   PubMed Web of Science ®Google Scholar
• Bolton D P, Cross K W. Further observations on cost preventing retrolental fibroplasia. Lancet 1974; 1: 445–448
   PubMed Web of Science ®Google Scholar
• Tin W, Milligan D W, Pennefather P, Hey E. Pulse oximetry, severe retinopathy, and outcome at one year in babies of less than 28 weeks gestation. Arch Dis Child Fetal Neonatal Ed 2001; 84: F106–F110
   PubMed Web of Science ®Google Scholar
• Anderson C G, Benitz W E, Madan A. Retinopathy of prematurity and pulse oximetry: A national survey of recent practices. J Perinatol 2004; 24: 164–168
   PubMedGoogle Scholar
• Sun S C. Relation of target SpO2 levels and clinical outcome in ELBW infants on supplemental oxygen. Pediatr Res 2002; 51: 350A
   Google Scholar
• CSMC Oxygen Administration Study Group. Can changes in clinical practice decrease the incidence of severe retinopathy of prematurity in very low birth weight infants?. Pediatrics 2003; 111: 339–345
   Google Scholar
• The STOP-ROP, Multicenter Study Group. Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP), a randomized, controlled trial. I: Primary outcomes. Pediatrics 2000; 105: 295–310
   Web of Science ®Google Scholar
• HOPE-ROP Multicenter Group. Retinopathy of prematurity outcome in infants with prethreshold retinopathy of prematurity and oxygen saturation > 94% in room air: The high oxygen percentage in retinopathy of prematurity study. Pediatrics 2002; 110: 540–544
   Google Scholar
• Askie L M, Henderson-Smart D J, Irwig L, Simpson J M. Oxygensaturation targets and outcomes in extremely preterm infants. N Engl J Med 2003; 349: 959–967
   PubMed Web of Science ®Google Scholar
• Phelps D L, Rosenbaum A L, Isenberg S L, et al. Tocopherol efficacy and safety for preventing retinopathy of prematurity: A randomized, controlled, double-masked trial. Pediatrics 1987; 79: 489–500
   PubMed Web of Science ®Google Scholar
• Schaffer D B, Johnson L, Quinn G E, et al. Vitamin E and retinopathy of prematurity. Follow up at 1 year. Ophthalmology 1985; 92: 1005–1011
   PubMedGoogle Scholar
• Reynold J D, Hardy R J, Kennedy K A, et al. Lack of efficacy of light reduction in preventing retinopathy of prematurity. N Engl J Med 1998; 338: 1572–1576
   Google Scholar
• Choi M Y, Park I K, Yu Y S. Long term refractive outcome in eyes of preterm infants with and without retinopathy of prematurity: Comparison of keratometric value, axial length, anterior chamber depth, and lens thickness. Br J Ophthalmol 2000; 84: 138–143
   PubMed Web of Science ®Google Scholar
• Knight-Nanan D M, Algawi K, Bowell R, O'Keefe M. Advanced cicatricial retinopathy of prematurity-outcome and complications. Br J Ophthalmol 1996; 80: 343–345
   Google Scholar
• Maly E. Frequency and natural history of retinopathy of prematurity (ROP). A prospective study in a Swedish city 1986–1990. Acta Ophthalmol Suppl 1993; 210: 52–55
   Google Scholar
• Kaiser R S, Trese M T, Williams G A, Cox M S, Jr. Adult retinopathy of prematurity: Outcomes of rhegmatogenous retinal detachments and retinal tears. Ophthalmology 2001; 108: 1647–1653
   PubMed Web of Science ®Google Scholar
• Sneed S R, Pulido J S, Blodi C F, et al. Surgical management of late-onset retinal detachments associated with regressed retinopathy of prematurity. Ophthalmology 1990; 97: 179–183
   Google Scholar
• Ashton N, Ward B, Serpell G. Effect of oxygen on developing retinal vessels with particular reference to the problem of retrolental fibroplasia. Br J Ophthalmol 1954; 38: 397–432
   PubMed Web of Science ®Google Scholar
• McLeod D S, Brownstein R, Lutty G A. Vaso-obliteration in the canine model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 1996; 37: 300–311
   PubMed Web of Science ®Google Scholar
• Smith L E, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy mouse. Invest Ophthalmol Vis Sci 1994; 35: 101–111
   PubMed Web of Science ®Google Scholar
• Donahue M L, Phelps D L, Watkins R H, et al. Retinal vascular endothelial growth factor (VEGF) mRNA expression is altered in relation to neovascularization in oxygen induced retinopathy. Curr Eye Res 1996; 15: 175–184
   PubMed Web of Science ®Google Scholar
• Stone J, Chan-Ling T, Pe'er J, et al. Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci 1996; 37: 290–299
   PubMed Web of Science ®Google Scholar
• Miller J W, Adamis A P, Shima D T, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994; 145: 574–584
   PubMed Web of Science ®Google Scholar
• Andreoli C M, Miller J W. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 2007; 18: 502–508
   PubMed Web of Science ®Google Scholar
• Shah P K, Narendran V, Tawansy K A, et al. Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol 2007; 55: 75–76
   PubMedGoogle Scholar
• Kong L, Mintz-Hittner H A, Penland R L, et al. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: A morphologic study. Arch Ophthalmol 2008; 126: 1161–1163
   PubMedGoogle Scholar
• Mintz-Hittner H A, Kuffel R R, Jr. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 2008; 28: 831–838
   PubMed Web of Science ®Google Scholar
• Sears J E. Anti-vascular endothelial growth factor and retinopathy of prematurity. Br J Ophthalmol 2008; 92: 14-37–38
   Google Scholar
• Smith L E, Shen W, Perruzzi C, et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 1999; 5: 1390–1395
   PubMed Web of Science ®Google Scholar
• Hellstrom A, Perruzzi C, Ju M, et al. Low IGF-I suppresses VEGF survival signaling in retinal endothelial cells: Direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci USA 2001; 98: 5804–5808
   PubMed Web of Science ®Google Scholar
• Hellstrom A, Engstrom E, Hard A L, et al. Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics 2003; 112: 1016–1020
   PubMed Web of Science ®Google Scholar
• Kermorvant-Duchemin E, Sennlaub F, Sirinyan M, et al. Trans-arachidonic acids generated during nitrative stress induce a thrombospondin-1-dependent microvascular degeneration. Nat Med 2005; 11: 1339–1345
   PubMed Web of Science ®Google Scholar
• Fierro I M, Kutok J L, Serhan C N. Novel lipid mediator regulators of endothelial cell proliferation and migration: Aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4). J Pharmacol Exp Ther 2002; 300: 385–392
   PubMed Web of Science ®Google Scholar
• Fliesler S J, Anderson R E. Chemistry and metabolism of lipids in the vertebrate retina. Prog Lipid Res 1983; 22: 79–131
   PubMed Web of Science ®Google Scholar
• SanGiovanni J P, Chew E Y. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog Retin Eye Res 2005; 24: 87–138
   PubMed Web of Science ®Google Scholar
• Calder P C. Polyunsaturated fatty acids and inflammation. Prostaglandins Leukot Essent Fatty Acids 2006; 75: 197–202
   PubMed Web of Science ®Google Scholar
• Salem N, Jr, Litman B, Kim H Y, Gawrisch K. Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 2001; 36: 945–959
   PubMed Web of Science ®Google Scholar
• Serhan C N, Savill J. Resolution of inflammation: The beginning programs the end. Nat Immunol 2005; 6: 1191–1197
   PubMed Web of Science ®Google Scholar
• Kang J X, Wang J, Wu L, Kang Z B. Transgenic mice: Fat-1 mice convert n-6 to n-3 fatty acids. Nature 2004; 427: 504
   PubMed Web of Science ®Google Scholar
• Connor K M, SanGiovanni J P, Lofqvist C, et al. Increased dietary intake of ω -3-polyunsaturated fatty acides reduces pathological retinal angiogenesis. Nat Med 2007; 13: 868–873
   PubMed Web of Science ®Google Scholar
• Crawford M A, Costeloe K, Ghebremeskel K, et al. Are deficits of arachidonic and docosahexaenoic acids responsible for the neural and vascular complications of preterm babies?. Am J Clin Nutr 1997; 66: 1032S–1041S
   PubMed Web of Science ®Google Scholar
• Honein M A, Paulozzi L J, Mathews T J, et al. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA 2001; 285: 2981–2986
   PubMed Web of Science ®Google Scholar
• Williams L J, Mai C T, Edmonds L D, et al. Prevalence of spina bifida and anencephaly during the transition to mandatory folic acid fortification in the United States. Teratology 2002; 66: 33–39
   PubMedGoogle Scholar
• Canfield M A, Collins J S, Botto L D, et al. Changes in the birth prevalence of selected birth defects after grain fortification with folic acid in the United States: Findings from a multi-state population-based study. Birth Defects Res A Clin Mol Teratol 2005; 73: 679–689
   Google Scholar